- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis
December 7th 2023, 10:30pm
San Antonio Breast Cancer Symposium
Treatment with trastuzumab deruxtecan generated clinical responses in patients with HER2-low or HER2-positive advanced breast cancer with pathologically confirmed leptomeningeal carcinomatosis.
T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 Expression
December 7th 2023, 7:27pm
San Antonio Breast Cancer Symposium
Administration of fam-trastuzumab deruxtecan significantly prolonged time-to-next treatment in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.
Disparities in Survival Outcomes Revealed With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer
December 7th 2023, 12:45am
San Antonio Breast Cancer Symposium
Precise stratification of hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays revealed comparable 3-year recurrence-free survival rates between Black and White patients despite observed racial differences in the distribution of molecular subtypes.
Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer
December 6th 2023, 11:27pm
San Antonio Breast Cancer Symposium
Jason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.
Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer
December 6th 2023, 11:15pm
San Antonio Breast Cancer Symposium
Heather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.
PFS Benefit Observed With Tucatinib Plus T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023, 10:25pm
San Antonio Breast Cancer Symposium
The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.
Maintenance Pembrolizumab/Olaparib Misses Survival End Points in Locally Advanced or Metastatic TNBC
December 6th 2023, 10:10pm
San Antonio Breast Cancer Symposium
Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.
BDC-1001 Plus Pertuzumab Is Under Exploration in HER2+ Breast Cancer
December 6th 2023, 9:10pm
San Antonio Breast Cancer Symposium
The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.
Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups
December 6th 2023, 8:29pm
San Antonio Breast Cancer Symposium
The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.
Capivasertib Maintains QOL Benefit Vs Placebo in HR+/HER2– Advanced Breast Cancer
December 6th 2023, 6:55pm
San Antonio Breast Cancer Symposium
Capivasertib plus fulvestrant did not negatively affect quality of life compared with placebo plus fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer.
AI Assistance Proves Safe, Decreases Time and Cost Burden of Sentinel Lymph Node Detection in Metastatic Breast Cancer
December 6th 2023, 5:45pm
San Antonio Breast Cancer Symposium
Utilizing an artificial intelligence–assisted workflow to detect sentinel lymph node metastases in patients with breast cancer was deemed safe according to current diagnostic standards and reduced the need for immunohistochemistry and its associated financial burden.
Ribociclib Plus Endocrine Therapy Improves PFS and OS in Elderly Patients With HR+/HER2– Breast Cancer
December 6th 2023, 3:55pm
San Antonio Breast Cancer Symposium
The combination of ribociclib and endocrine therapy led to an improvement in progression-free survival and overall survival vs placebo plus endocrine therapy in patients with hormone receptor-positive/HER2-negative advanced breast cancer across all age groups.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
November 27th 2023, 6:52pm
Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.
Dr Habib on Developments in Palliative Care For Patients With Cancer
November 27th 2023, 6:43pm
M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
November 22nd 2023, 7:25pm
Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
November 21st 2023, 9:22pm
Rutgers Cancer Institute of New Jersey's Annual Oncology Clinical Practice and Research Summit
Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the increased incidence of gastric cancer in minority patient populations, highlighting the disparities that lead to these patient outcomes in the United States.
CAR-M Therapy CT-0508 Shows Promise in HER2-Overexpressing Recurrent/Metastatic Solid Tumors
November 19th 2023, 11:00am
The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.
Dr Ecker on the Investigation of the Microbiome in Pancreatic Cancer
November 17th 2023, 10:40pm
Rutgers Cancer Institute of New Jersey's Annual Oncology Clinical Practice and Research Summit
Brett L. Ecker, MD, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.
Dr Kalinsky on Remaining Treatment Questions in Breast Cancer
November 17th 2023, 10:37pm
Bridging the Gaps in Breast Cancer
Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.
Dr Basho on Treatment Considerations With ADCs in Breast Cancer
November 17th 2023, 10:34pm
Bridging the Gaps in Breast Cancer
Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.